PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement.
暂无分享,去创建一个
S. Barrington | N. Mikhaeel | R. Carr | A. Khan | L. Cameron | A. Hunt | Timothy Morris
[1] B. Cheson. Hodgkin lymphoma: protecting the victims of our success. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Bøgsted,et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] L. Gordon,et al. Lack of benefit of central nervous system prophylaxis for diffuse large B‐cell lymphoma in the rituximab era , 2012, Cancer.
[4] T. Siegal,et al. CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom? , 2012, Blood reviews.
[5] G. Bisi,et al. Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study. , 2011, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[6] Yen-Kung Chen,et al. F-18 FDG PET for Evaluation of Bone Marrow Involvement in Non-Hodgkin Lymphoma: A Meta-analysis , 2011, Clinical nuclear medicine.
[7] Bruce D Cheson,et al. Role of functional imaging in the management of lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Gascoyne,et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Ora Israel,et al. 18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients , 2010, Journal of Nuclear Medicine.
[10] R. Gascoyne,et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.
[11] N. Smeeton,et al. Observer Variation in Interpreting 18F-FDG PET/CT Findings for Lymphoma Staging , 2009, Journal of Nuclear Medicine.
[12] R. Gascoyne,et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. , 2009, Blood.
[13] N. Schmitz,et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). , 2009, Blood.
[14] P. Gaulard,et al. Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[15] Y. Bang,et al. Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement , 2009, Annals of Hematology.
[16] J. Leonard,et al. Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] Thomas C Kwee,et al. Imaging in staging of malignant lymphoma: a systematic review. , 2008, Blood.
[18] P. Royston,et al. Multivariable model-building , 2008 .
[19] G. Salles,et al. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Matthews,et al. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement , 2006, European journal of haematology.
[21] A. Nagler,et al. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] T. Hany,et al. Bone involvement in patients with lymphoma: the role of FDG-PET/CT , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[23] J. Ioannidis,et al. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[24] J. Ioannidis,et al. 18 F-FDG PET for Evaluation of Bone Marrow Infiltration in Staging of Lymphoma: , 2005 .
[25] M. Baccarani,et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients , 2004, British Journal of Cancer.
[26] A. Alavi,et al. Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin's lymphoma can simulate lymphoma involvement in marrow. , 2004, Clinical lymphoma.
[27] A. Alavi,et al. Utility of FDG-PET scanning in lymphoma by WHO classification. , 2003, Blood.
[28] J. D. van der Walt,et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. , 1998, Blood.
[29] J. Concato,et al. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. , 1995, Journal of clinical epidemiology.
[30] J. Cotelingam,et al. Bone marrow involvement in large-cell lymphoma. Prognostic implications of discordant disease. , 1994, American journal of clinical pathology.
[31] D. Weisenburger,et al. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] G. Zei,et al. Bone marrow and blood involvement by non‐Hodgkin's lymphoma: A study of clinicopathologic correlations and prognostic significance in relationship to the Working Formulation , 1989, European journal of haematology.